4D Molecular Therapeutics, Inc.
NASDAQ: FDMT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David H. Kirn
- Employees
- 227
- Headquarters
- EmeryVille, United States
- IPO year
- 2020
- Market cap
- $607.5M
- Website
- https://www.4dmoleculartherapeutics.com
Loading FDMT…
Loading profile data…Frequently asked questions about FDMT
What does 4D Molecular Therapeutics, Inc. (FDMT) do?
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmono...
Where does FDMT trade?
4D Molecular Therapeutics, Inc. (FDMT) trades on the NASDAQ Global Select.
What sector is FDMT in?
4D Molecular Therapeutics, Inc. (FDMT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of 4D Molecular Therapeutics, Inc.?
David H. Kirn is the chief executive officer of 4D Molecular Therapeutics, Inc. (FDMT).
Where is 4D Molecular Therapeutics, Inc. headquartered?
4D Molecular Therapeutics, Inc. is headquartered in United States.
Does FDMT pay a dividend?
4D Molecular Therapeutics, Inc. (FDMT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FDMT go public?
4D Molecular Therapeutics, Inc. (FDMT) completed its initial public offering in 2020.